Russell Investments Group Ltd. Has $24.92 Million Stock Holdings in argenx SE (NASDAQ:ARGX)

Russell Investments Group Ltd. trimmed its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 7.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 40,520 shares of the company's stock after selling 3,432 shares during the period. Russell Investments Group Ltd. owned 0.07% of argenx worth $24,920,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in ARGX. Stifel Financial Corp lifted its position in shares of argenx by 15.3% in the third quarter. Stifel Financial Corp now owns 8,832 shares of the company's stock worth $4,788,000 after purchasing an additional 1,170 shares in the last quarter. Stephens Inc. AR purchased a new stake in argenx in the 4th quarter worth approximately $310,000. Ritholtz Wealth Management boosted its stake in shares of argenx by 85.5% during the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock valued at $552,000 after buying an additional 414 shares during the period. Jones Financial Companies Lllp grew its holdings in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after acquiring an additional 61 shares in the last quarter. Finally, MML Investors Services LLC increased its stake in shares of argenx by 16.9% in the third quarter. MML Investors Services LLC now owns 8,699 shares of the company's stock worth $4,715,000 after acquiring an additional 1,255 shares during the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Stock Performance

Shares of NASDAQ:ARGX traded up $16.66 during trading on Monday, hitting $597.60. 244,553 shares of the stock were exchanged, compared to its average volume of 306,764. The company has a market capitalization of $36.31 billion, a price-to-earnings ratio of -679.09 and a beta of 0.60. argenx SE has a 1-year low of $352.77 and a 1-year high of $678.21. The company's fifty day simple moving average is $607.87 and its 200-day simple moving average is $604.46.

Remove Ads

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. On average, research analysts forecast that argenx SE will post 3.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ARGX shares. JMP Securities upped their target price on argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a research report on Tuesday, January 14th. Piper Sandler increased their price objective on argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a report on Tuesday, January 7th. HC Wainwright reiterated a "buy" rating and issued a $720.00 target price on shares of argenx in a research note on Tuesday, April 8th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. Finally, Guggenheim lifted their price objective on shares of argenx from $775.00 to $1,100.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, argenx presently has an average rating of "Moderate Buy" and a consensus target price of $690.33.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.